The study compared fixed (time-limited) treatment with continuous treatment for chronic lymphocytic leukemia (CLL). The results showed that fixed treatment with the combination of venetoclax and obinutuzumab produced better results than traditional chemoimmunotherapy in patients without comorbidities, including longer survival without disease progression[1]. Continuous treatment, for example with ibrutinib, prolongs overall and progression-free survival, but requires long-term drug administration[6]. Fixed treatment makes it possible to stop therapy after achieving remission, which can improve patients' quality of life and reduce the risk of side effects[1][5]. Chemoimmunotherapy remains the standard for younger and physically fit patients, but targeted therapies such as venetoclax and ibrutinib are changing treatment strategies[3][5]. Maintenance therapy after achieving remission may include oral targeted drugs to help maintain response to treatment[4][5]. Overall, the study supports the use of fixed therapy as an effective alternative to continuous therapy in appropriately selected CLL patients.